Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
2.
Br J Haematol ; 130(3): 391-3, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16042688

ABSTRACT

Summary The purpose of this study was to evaluate telomere length in peripheral blood granulocytes and mononuclear cells collected from 22 women with polycythaemia vera (PV) and essential thrombocythaemia (ET). PV and ET are chronic myeloproliferative diseases whose heterogeneity of stem cell origin and clonal development has been established through analysis of X-chromosome inactivation patterns. The results from clonality assay and determination of telomere length show that only clonal granulocytes have shortened telomeres.


Subject(s)
Granulocytes/ultrastructure , Polycythemia Vera/immunology , Telomere/ultrastructure , Thrombocythemia, Essential/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Case-Control Studies , Clone Cells , Female , Hematopoietic Stem Cells/ultrastructure , Humans , Image Processing, Computer-Assisted , Leukocytes, Mononuclear/ultrastructure , Middle Aged , Polycythemia Vera/complications , Thrombocythemia, Essential/complications
3.
Blood ; 105(5): 2138-40, 2005 Mar 01.
Article in English | MEDLINE | ID: mdl-15494424

ABSTRACT

Essential thrombocythemia (ET) and polycythemia vera (PV) are chronic myeloproliferative disorders that share the involvement of a multipotent progenitor cell and dominance of the transformed clone over normal hematopoiesis. On the other hand, the heterogeneity of these diseases with respect to clonal development from a common progenitor has been well established. To identify useful prognostic indicators, we analyzed telomerase activity (TA), a known marker of neoplastic proliferation, in granulocytes (PMNs) and mononuclear cells (MNCs) from 22 female patients with ET and PV. Clonality status was determined by investigation of X chromosome inactivation patterns (XCIPs). We found a statistically significant positive correlation between high TA and monoclonal pattern of XCIP. Therefore, our data suggest that the use of multiple tumor markers may contribute to a better understanding of the deregulated physiology of these disorders and provide useful prognostic factors.


Subject(s)
Granulocytes/pathology , Polycythemia Vera/pathology , Telomerase/metabolism , Thrombocythemia, Essential/pathology , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Clone Cells , Dosage Compensation, Genetic , Female , Granulocytes/metabolism , Humans , Leukocytes, Mononuclear/metabolism , Middle Aged , Polycythemia Vera/genetics , Prognosis , Thrombocythemia, Essential/genetics
4.
Eur J Haematol ; 70(4): 225-30, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12656745

ABSTRACT

OBJECTIVE: Vaccination against influenza in patients with chronic lymphoproliferative disorders (CLPD) and multiple myeloma (MM) is still a matter of clinical uncertainty. The aim of this study was to determine the safety, immunogenicity and clinical response to a commercially available vaccine against influenza in a group of such patients. METHODS: Thirty-four patients with CLPD and MM and 34 immunologically normal subjects were vaccinated with the same vaccine against influenza. Patients were observed during the epidemic season from October 1999 to April 2000, and monitored for side-effects of the vaccine, seroprotection and seroconversion after vaccination. The prevaccination level of immunoglobulins was also determined. Occurrence of influenza episodes was demonstrated with the positive isolation of a viral strain from a pharyngeal swab. RESULTS: No patient had untoward reactions to the vaccine used. Seroconversion and seroprotection were up to the standard established by the European Agency for the Evaluation of Medicinal Products. Only one patient developed influenza during follow-up. CONCLUSIONS: Influenza vaccine is effective and well tolerated in patients with CLPD and MM. No contraindications exist for its use, and it should become a routine practice, in order to prevent serious complications during the influenza epidemic season.


Subject(s)
Influenza Vaccines/immunology , Influenza, Human/prevention & control , Lymphoproliferative Disorders/immunology , Multiple Myeloma/immunology , Vaccination , Adult , Aged , Aged, 80 and over , Antibodies, Viral/biosynthesis , Antibodies, Viral/blood , Female , Follow-Up Studies , Hemagglutination Inhibition Tests , Humans , Immunoglobulins/analysis , Influenza A virus/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Lymphoma/immunology , Male , Middle Aged , Safety , Seasons , Vaccination/adverse effects
5.
Br J Haematol ; 119(3): 833-8, 2002 Dec.
Article in English | MEDLINE | ID: mdl-12437668

ABSTRACT

Methylene blue (MB) is a powerful reducing agent that is widely used in clinical practice as well as for metabolic studies of the erythrocyte. We have investigated the role of catalase as a specific enzyme for the removal of hydrogen peroxide by measuring the in vitro effects of MB on human red cells. In the presence of MB, catalase underwent inactivation even with the co-existence of active generation of NADPH, leaving the glutathione concentration unaffected. The data obtained in the present investigation show, using a different tool (MB), that catalase is the active enzyme in H2O2 detoxification and that its integrity is largely dependent on an adequate generation of NADPH.


Subject(s)
Catalase/physiology , Enzyme Inhibitors/pharmacology , Erythrocytes/enzymology , Hydrogen Peroxide/metabolism , Methylene Blue/pharmacology , Catalase/antagonists & inhibitors , Glutathione/metabolism , Glutathione/physiology , Humans , In Vitro Techniques , NADP/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...